Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health Corporation    CVS

CVS HEALTH CORPORATION (CVS)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

CVS Caremark 4th-Quarter Profit Up 2.6% on Higher Sales

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/06/2013 | 02:59pm CEST

--Debt refinancing costs weigh on bottom line, but sales broadly higher

--PBM, retail sales each rise, helping CVS report better-than-expected results

--Same-store sales growth exceeds monthly data posted by Walgreen, Rite Aid

(Updates with CEO interview comments, additional background and the latest stock quote, beginning in the first paragraph.)

 
   By John Kell 
 

CVS Caremark Corp.'s (>> CVS Caremark Corporation) fourth-quarter earnings rose 2.6% as debt refinancing costs weighed on the bottom line, somewhat masking a strong performance for the company's pharmacy-benefits-management business and higher retail sales.

The drugstore retailer and PBM has now reported better-than-expected adjusted earnings for four consecutive quarters. Results in the fourth quarter were led by the PBM business, which saw revenue rise 17% to $18.6 billion, aided by new clients added to the network during the 2012 PBM selling season, higher drug costs and growth in the Medicare Part D program.

On the retail side, the top line jumped 5.1% to $16.3 billion as same-store sales grew 4%, growth that exceeds the monthly sales data posted by rivals Walgreen Co. (>> Walgreen Company) and Rite Aid Corp. (>> Rite Aid Corporation) in late 2012. Prescription volume growth was healthy, aided by client wins after Walgreen's contract dispute last year with fellow PBM Express Scripts Holding Co. (>> Express Scripts Holding Co) and stronger demand for flu-related prescriptions.

But CVS said pharmacy same-store sales were stung by higher usage of low-priced generics, which hurts the top line for drug store chains, though those products have a mixed benefit as they command higher margins.

An active flu season has helped drugstore chains somewhat mitigate the top-line dent caused by higher generic penetration, as consumers seek out vaccinations, order prescriptions and buy over-the-counter cough-and-cold medications. CVS Chief Executive Larry Merlo told Dow Jones Newswires that the company saw a "significant uptick" in flu activity by mid-December and strong demand through most of January.

Mr. Merlo said over the past two weeks, CVS has seen the severity of flu cases moderate. Still, the company has administered about 4.8 million flu shots so far this season, above last year's level.

Overall, CVS reported a profit of $1.13 billion, or 90 cents a share, up from $1.1 billion, or 81 cents a share, a year earlier. Excluding debt-related costs and other items, adjusted earnings from continuing operations were $1.14 in the latest quarter. Revenue increased 11% to $31.39 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.10 on revenue of $31.13 billion.

Gross margin expanded to 20.1% from 19.6%.

For the year, CVS now sees adjusted earnings from continuing operations of $3.86 to $4, a view that was lifted by two cents to reflect the debt refinancing.

CVS will face some lofty comparisons in 2013, due to strong demand for generics, particularly in the first half of the year. And after Walgreen inked a contract agreement with Express Scripts starting in September, the company has had some success winning back some customers it lost to competitors during the months-long spat, resulting in some lost business for CVS.

Shares were up 1.5% to $52.50 in premarket trading.

--Tess Stynes contributed to this article

Write to John Kell at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article
ChangeLast1st jan.
CVS HEALTH CORPORATION 1.40% 66.03 Delayed Quote.-10.18%
EXPRESS SCRIPTS HOLDING CO 0.36% 77.08 Delayed Quote.3.27%
RITE AID CORPORATION 0.00% 1.66 Delayed Quote.-13.71%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH CORPORATION
05/25Pfizer to pay $23.85 million to settle U.S. co-payment kickback probe
RE
05/18CVS HEALTH : AG Curtis Hill Lauds CVS Officials for Drug-Disposal Plans
AQ
05/17CVS HEALTH : AG Curtis Hill to Join CVS Officials to Discuss Drug Disposal
AQ
05/14U.S. to consider expanding Medicare drug price negotiation
RE
05/14CVS HEALTH : Thinking about buying stock in Apple, CVS Health Corp, Facebook, Sy..
PR
05/12CVS HEALTH : installs medication disposal units across the state
AQ
05/12Trump assails high drug prices, avoids direct hit on industry
RE
05/11Trump's Plan to Cut Drug Prices Leaves Industry Relieved
DJ
05/11CVS HEALTH : Foundation gives $20K to Free Clinic of Meridian
AQ
05/11CVS HEALTH : Statement on Trump Administration Initiative to Reduce Drug Costs
PR
More news
News from SeekingAlpha
05/25Tracking Larry Robbins' Glenview Capital Management Portfolio - Q1 2018 Updat.. 
05/24Thomson Reuters Retail And Restaurant Aggregate Estimates And Revisions Q1 20.. 
05/24TOP WALL STREET HEALTHCARE GAINERS F : Allergan, CVS Health, Patterson, Sanofi, .. 
05/22GOLDMAN SACHS : Hedge funds betting against Nvidia, Intel 
05/2110 Dividend Growth Stocks For May 2018 
Financials ($)
Sales 2018 189 B
EBIT 2018 9 961 M
Net income 2018 5 331 M
Debt 2018 19 170 M
Yield 2018 3,03%
P/E ratio 2018 12,92
P/E ratio 2019 10,05
EV / Sales 2018 0,46x
EV / Sales 2019 0,43x
Capitalization 67 129 M
Chart CVS HEALTH CORPORATION
Duration : Period :
CVS Health Corporation Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 86,4 $
Spread / Average Target 31%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH CORPORATION-10.18%67 129
WALGREENS BOOTS ALLIANCE-12.68%63 001
EXPRESS SCRIPTS HOLDING CO3.27%43 297
MCKESSON CORPORATION-6.50%30 086
AMERISOURCEBERGEN-6.89%18 791
CARDINAL HEALTH-14.41%16 503